Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

All in all, PHAT has 6 recent analyst reviews that break down into 5 Buys and 1 Hold, giving the stock a Strong Buy consensus rating. The shares are priced at $17.66 and have an average price target ...

This milestone marks Enveda's third asset to enter clinical development, following ENV-294 (atopic dermatitis and asthma) and ENV-308 (obesity), underscoring the productivity of the company's platform ...

Expanding bispecific antibody access for multiple myeloma involves collaboration between academic centers and community ...

Telehealth Platform Offers Compounded GLP-1 Injections and Oral Tablets at $299/Month With No Contract as 100,000+ Patients Seek Affordable Semaglutide Access Heading Into New Year Weight Loss Season ...

Key challenges include logistical hurdles, such as the need for specialized training and infrastructure, and financial ...

News from the week beginning 15th December 2025 includes items from, @BlackLine, @CybageSoftware, @Deltek, @Epicor, @Ultimo, @Interprefy, @Klient, @NetApp, @People2.0, @Percona, @Planful, ...

Clearwater Analytics ("CWAN" or the "Company"), announced that it has entered into a definitive agreement to be acquired in a transaction valued at approximately $8.4 billion by a Permira and Warburg ...

Remote work and high salaries can go hand in hand. Many professionals, especially those with sought-after credentials and experience, earn top dollar in high-paying remote jobs that offer more ...

Oracle still looks more like a hold than a sell, with fast‑growing cloud and AI revenue and a Street “Moderate Buy” rating with about 70% implied upside.

Objectives Given the rapidly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles and real-world outcomes ...

Third-Party Lab Testing, Bioavailability Questions, and Regulatory Status ExaminedCARPINTERIA, Dec. 23, 2025 (GLOBE NEWSWIRE) ...